摘要:
An extract and/or herbal fraction and pharmaceutical preparation include extract of Phaleria macrocarpa which for the purpose of this invention, is referred to as DLBS1449. The herbal extract according to the teaching of this invention is effectively applicable to inhibit the expression and activity of Cholesteryl Ester Transferase Protein (CETP), increase HDL cholesterol level, decrease LDL cholesterol level without raising blood pressure therefore it is further applicable in atherosclerosis therapy.
摘要:
Extract and/or fraction from Cinnamomum burmanii (DLBS2411) related to its extraction method and its biological activities show activities as antiulcer by conferring mucoprotection and down-regulating H+/K+ ATPase. Treatment with DLBS2411 decreases the H+/K+ ATPase mRNA level in HEK 293 and gastric parietal cells. In addition, DLBS2411 inhibits activity of H+/K+ ATPase gastric enzyme wherein pH influences this inhibition mechanism. DLBS2411 also has characteristic as antioxidant which is shown by the increase of reducing power as the given dosage increases.
摘要翻译:与其提取方法相关的樟树(DLBS2411)的提取物和/或分数及其生物活性通过赋予保护和下调H + / K + ATP酶显示出作为抗溃疡的活性。 用DLBS2411处理可降低HEK 293和胃壁细胞中的H + / K + ATPase mRNA水平。 此外,DLBS2411抑制H + / K + ATP酶胃酶的活性,其中pH影响这种抑制机制。 DLBS2411还具有作为抗氧化剂的特征,其随着给定剂量增加而降低功率的增加而显示。
摘要:
A pharmaceutical composition comprising a substantially coumarin-free extract derived from cinnamon. Its production method including some steps: grinding the raw material, extracting raw material from previous step by maceration using a first solvent to obtain crude extract of Cinnamomum burmanii, fractionating the extracted raw material from previous step through liquid-liquid extraction using a second solvent, wherein the second solvent is immiscible with the first solvent to obtain substantially coumarin-free extract, and optionally drying the substantially coumarin-free extract.The pharmaceutical composition comprising the substantially coumarin-free extract as a single component or in a combination with suitable pharmaceutical excipient(s) to produce a pharmaceutical composition that is safe to be consumed daily and in long-term use.
摘要:
The invention concerns compounds DLBS1425E2.2 and DLBS1425F1 isolated and identified from the extract of the plant Phaleria macrocarpa (Scheff.) Boerl. The invention also relates to the use of said compounds, either as a single active compound or in combination, in a pharmaceutical dosage form that has anti-proliferative activity of cancer cells, and its use relating to female related diseases. Formula (I).
摘要:
A herbal extract composition from Lythraceae and Lauraceae family plants and its usage as insulin resistance reducer, syndrome X normalization, pre-diabetes and type 2 diabetes treatments, particularly as activator in insulin signal pathway, as modulator in glucose transport system, as modulator in adiponectin secretion, and as suppressor in insulin resistance. Representative from Lythraceae family has been selected Lagerstroemia speciosa, and representative from Lauraceae family has been selected Cinnamomum burmannii. Such herbal extract composition work synergistically to strengthen pharmacological effect produced by each extract if they act alone.
摘要:
A pharmaceutical dosage form comprising an extract of Phaleria macrocarpa which has antineoplastic, anti-inflammatory, and antiangiogenic activity. Its use as an antineoplastic agent is to inhibit tumour growth. Its use as an anti-inflammatory agent is to relieve inflammation and pain, and also as an antipyretic. Another use is as an antiangiogenic agent to inhibit the growth of new blood vessels to prevent cancer metastasis.
摘要:
The invention concerns compounds DLBS1425E2.2 and DLBS1425F1 isolated and identified from the extract of the plant Phaleria macrocarpa (Scheff.) Boerl. The invention also relates to the use of said compounds, either as a single active compound or in combination, in a pharmaceutical dosage form that has anti-proliferative activity of cancer cells, and its use relating to female related diseases. Formula (I).
摘要:
A pharmaceutical composition comprising a substantially coumarin-free extract derived from cinnamon. Its production method including some steps: grinding the raw material, extracting raw material from previous step by maceration using a first solvent to obtain crude extract of Cinnamomum burmanii, fractionating the extracted raw material from previous step through liquid-liquid extraction using a second solvent, wherein the second solvent is immiscible with the first solvent to obtain substantially coumarin-free extract, and optionally drying the substantially coumarin-free extract.The pharmaceutical composition comprising the substantially coumarin-free extract as a single component or in a combination with suitable pharmaceutical excipient(s) to produce a pharmaceutical composition that is safe to be consumed daily and in long-term use.
摘要:
A herbal extract composition from Lythraceae and Lauraceae family plants and its usage as insulin resistance reducer, syndrome X normalization, pre-diabetes and type 2 diabetes treatments, particularly as activator in insulin signal pathway, as modulator in glucose transport system, as modulator in adiponectin secretion, and as suppressor in insulin resistance. Representative from Lythraceae family has been selected Lagerstroemia speciosa, and representative from Lauraceae family has been selected Cinnamomum burmannii. Such herbal extract composition work synergistically to strengthen pharmacological effect produced by each extract if they act alone.